Citations

Clear

65 citation(s) found for "Hill, Matthew".

Nasal Alar Subunit Reconstruction: A Review of Data
Menapace, Deanna C., Shockley, W. , Miller, Matthew, Clark, J. Madison, Menapace, Denna C.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | July 22, 2026 | Volume: 11 | Issue: 4 | Pages: No page available

10.1002/lio2.70494 | PMID 42487898 Get It

ABSTRACT Objectives Alar reconstruction is common, yet high‐quality outcomes data are limited. This review synthesizes the available literature to guide evidence‐informed reconstructive choices. Methods A systematic review identified 35 eligible studies reporting defect characteristics, techniques, and aesthetic, functional, and graft/flap outcomes. Single‐patient case reports, purely technical papers, and studies without outcome data were excluded. Results Full‐thickness skin grafts (FTSG), FTSG with cartilage, and composite grafts have been used with acceptable aesthetic outcomes for small defects. Local flaps are most common for small to intermediate defects, while regional flaps, particularly melolabial (MLF) and paramedian forehead flaps (PMFF), are the primary options for larger defects. PMFFs have higher reported cosmetic satisfaction but may require more secondary procedures. Conclusions Standard data and evidence reporting for alar subunit reconstruction is very limited, with a predominance of retrospective and technique‐driven studies and gestalt‐based outcomes. Standardized reporting of defect size, functional outcomes, and validated patient‐reported measures is needed. Until higher‐quality data is available, reconstructive decisions should be individualized.
Variation in Chronic Automated Red Cell Exchange Practices for Sickle Cell Disease: Insights Into Isovolemic Hemodilution Use
Jones, Jennifer M. , Aldarweesh, Fatima , Aqui, Nicole, Bobr, Aleh , Brunker, Patricia A. R. , Covington, Mischa L. , Guarente, Juliana , Hagar, Robert, Karafin, Matthew, Lamba, Divjot Singh , Lee, Grace M. , Mack, Ethan A. , Muthur, Gagan, Nazli, Saadiya, Olaniyan, H S, Raval, Jay S., Setya, Divya , Tanhehco, Yvette C. , Thant, Mamie, Wu, Yanyun , Wong, Edward C.C. , Zheng, Yan , Brunker, Patricia A R , Lee, Grace , Lu, Wen , Mack, Ethan A , Onyenekwu, Chinelo P , Setya, Divya , Tanhehco, Yvette C , Vivero, Angelica , Yurtsever, Nalan , Zheng, Yan , Shi, Patricia A , Webb, Jennifer , Aldarweesh, Fatima , Aqui, Nicole A., Hagar, Robert Ward, Lu, Wen , Nazli, Saadiya , Yurtsever, Nalan , Shi, Patricia A.

Mayo Clinic

Journal of Clinical Apheresis | June 19, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70146 | PMID 42316838 Get It

ABSTRACT Prior surveys of chronic automated red blood cell exchange (RCE) for patients with sickle cell disease (SCD) have identified considerable procedural variability, especially with the use of isovolemic hemodilution red blood cell exchange (IHD‐RCE). We conducted a survey of chronic RCE practices among American Society for Apheresis (ASFA) members to identify opportunities for practice harmonization and future studies. The ASFA SCD Research Subcommittee developed a 72‐item survey of chronic RCE practices, with a focus on IHD‐RCE. The survey was validated internally and distributed by email to all ASFA members from September 2024 to February 2025. One survey response from each institution was retained for data analysis. Descriptive statistics were performed. Sixty‐two survey responses, including three from international institutions, were retained for analysis. Sixty‐one percent of respondents (38/62) reported using at least one fixed RCE target, with end hematocrit being the most common fixed parameter (40%, 25/62), followed by fraction of cells remaining (31%, 19/62) and hemoglobin S% (27%, 17/62). Most respondents (60%, 37/61) performed IHD‐RCE at their institution, though other details such as the minimum hematocrit, exclusion criteria, and response to adverse effects were variable. Consistent pre‐ and post‐RCE laboratory monitoring practices were reported. Consistent with earlier surveys, procedural variability in chronic RCE practices for patients with SCD is observed. This highlights opportunities to compare outcomes where practice variability exists. Consensus guidelines based on institutional practices with optimal outcomes should be developed.
Anti-fibrinolytic strategies improve liver regeneration in mice and reduce post-hepatectomy liver failure in patients
Li, Zhihao , Wei, Zimu , Groeneveld, Dafna J. , Strilchuk, Amy W. , Flick, Matthew J., Dong, Yawen , Podrascanin, V. , Truty, Mark, Kendrick, Michael L., Cleary, S., Warner, Susanne G., Assinger, Alice, Kastrup, Christian J. , Karanicolas, Paul, Starlinger, P, Smoot, Rory L , Kastrup, Christian J , Luyendyk, James P , Li, Zhihao , Dong, Yawen , Flick, Matthew J. , Truty, Mark J. , Kendrick, Michael L. , Cleary, Sean P. , Warner, Susanne G. , Smoot, Rory L. , Assinger, Alice , Karanicolas, Paul J. , Luyendyk, James P.

Mayo Clinic

Blood Journal | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025029780 | PMID 42275251 Get It

Pharmacological plasminogen reduction enhanced liver regeneration experimentally and clinically. siRNA-induced plasminogen deficiency promoted hepatocyte proliferation after partial hepatectomy in mice, contrasting genetic deficiency models. In the HeLiX trial, tranexamic acid reduced post-hepatectomy liver failure odds, suggesting a novel therapeutic strategy.
Red cell antibody and antigen patterns in patients with sickle cell disease: A multi‐center analysis
Covington, Mischa L. , Conrad, Stephanie , Evans, Mariama I., Fasano, Ross M., Forbes, Judith A, Johnson, Carolyn, Karafin, Matthew S. , Nakahara, Hirotomo , Poisson, Jessica , Sikora, James , Sofoluwe, Adeyemi Victor, Sullivan, Jensyn Cone , Thomasson, Reggie R. , Conrad, Stephanie , Karafin, Matthew , Campbell-Lee, Sally , Nakahara, Hirotomo , Poisson, Jessica L , Sikora, James , Cone Sullivan, Jensyn , Thomasson, Reggie R , Lu, Wen , Allen, Elizabeth S. , Chou, Stella T. , Fasano, Ross M. , Juskewitch, Justin E. , Stowell, Sean R. , Lu, Wen

Mayo Clinic

Transfusion | April 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/trf.70213 | PMID 41968490 Get It

Abstract Background Red cell alloimmunization complicates sickle cell disease (SCD) management despite current widespread prophylactic Rh/K matching in the United States (US). Regional antibody patterns remain poorly characterized. Study Design and Methods We conducted a retrospective analysis of 2965 SCD patients from 9 US sites (2010–2022). All hospitals prophylactically match for Rh and K antigens. Each site collected demographics, antigen status, antibody histories, and antibody screen results from their laboratory information system. Results Overall antibody prevalence was 29.7% with dramatic institutional variation (17.9%–56.0%). Alloantibody prevalence was 27.5%. Most autoantibody‐positive patients (74.23%) also had alloantibodies, identifying a high‐risk population. A third of patients with positive antibody histories had negative screens. Pediatric patients showed markedly different antibody profiles than adults. Hospitals’ antibody patterns clustered by patient age rather than geography. Rh and K antibodies were the most common and also most likely to co‐occur, followed by S, Fya, and Jkb antibodies. Antibodies against Jsa (1.82%), V (1.75%), and Kpa (1.69%) were more prevalent than anti‐Jka (1.28%). Despite regional antibody variation, antigen frequencies remained overall consistent. In antigen–antibody pairwise comparisons, 3.15% were antigen‐negative and antibody‐positive reflecting alloimmunization; 0.47% were both antibody‐ and antigen‐positive, suggesting partial/variant antigens. Discussion Substantial institutional variation in antibody prevalence suggests need for site‐specific approaches to testing and prophylactic matching. High co‐occurrence of auto‐ and alloantibodies, antibody immunogenicity patterns, and antigen–antibody discordances support the need for further research and consideration of refined testing and/or matching strategies beyond the current Rh and K standard.
Impact of HER2 expression and ERBB2 alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
Reyes, Kevin R., Zhang, Li , Cai, Elise Y. , Thomas, Zachariah, Oh, Eugene , Zhong, Jeffrey Yinhong, Jaime-Casas, Salvador, Milowsky, M., Nizam, Amanda, Shah, Sumit , Basu, Arnab, Grivas, Petros, Tripathi, Abhishek, Campbell, Matthew T., Koshkin, Vadim S. , Zhang, Li , Zhang, Li, Jiang, Cindy Y. , Jindal, Tanya , Zhong, Jeffrey Yinhong , Jaime‐Casas, Salvador , Milowsky, Matthew I. , Nizam, Amanda , Grivas, Petros , Tripathi, Abhishek , Brown, Jason R. , Alhalabi, Omar , Tsung, Irene , Campbell, Matthew T.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 794-794

10.1200/jco.2026.44.7_suppl.794 Get It

794 Background: HER2 protein, encoded by ERBB2 gene, is the target of emerging therapies for patients (pts) with advanced urothelial carcinoma (aUC). High HER2 IHC expression (IHC 3+) is present in ~15% of pts with aUC, while >50% of pts have HER2 IHC 1+/2+/3+ expression. EVP is the preferred 1 st line regimen for pts with aUC, but the impact of HER2 status on EVP outcomes is unclear. Methods: We identified pts from the UNITE study with tumor samples tested for HER2 by IHC and another cohort with next-generation sequencing (NGS) data available. Outcomes were compared by HER2 IHC status (HER2 IHC 0/1+ vs 2+/3+) and separately based on ERBB2 status (alteration vs wild-type). X 2 test was used to compare observed response rate (ORR) and logistic regression was used to compare disease control rate (DCR). Duration of response (DOR), progression-free survival (PFS) and overall survival (OS) from EVP start were evaluated using log-rank test and Cox proportional hazards models. Multivariate analysis (MVA) included age, sex, race, ECOG PS, neutrophil:lymphocyte ratio, albumin, hemoglobin, primary tumor site, tumor histology, prior lines of treatment, and metastatic sites as covariates. Results: Among 521 pts treated with EVP from 16 sites, 112 had HER2 IHC data and 313 had NGS. Median age was 71, 74% were men, 84% Caucasian, 82% had ECOG PS 0-1, 65% pure urothelial histology, and 73% received frontline EVP. HER2 IHC distribution (n=112) was 27%/21%/37%/15% for 0/1+/2+/3+, respectively. ERBB2 alterations were present in 14% (44/313). Baseline characteristics were similar in HER2 0/1+ and 2+/3+ pts, except more primary bladder tumors in 2+/3+ pts (83% vs 63%, p=0.01). For the overall cohort (n=521), with a median follow up of 7.3 mos from EVP start, ORR was 54%, DCR 81%, median DOR (mDOR) 8.5 mos, median PFS (mPFS) 8.5 mos, and median OS (mOS) 19.8 mos. Pt outcomes by HER2 IHC status are shown (Table). In univariate analysis (UVA), pts with HER2 IHC 0/1+ had longer mOS compared to HER2 IHC 2+/3+, but this was not significant in MVA (HR: 0.5; CI: 0.2–1.3, p=0.17). No significant differences were observed in other outcomes. Evaluating clinical outcomes by ERRB2 status, no significant differences were seen for ERBB2 -altered vs wild-type pts. Conclusions: In this retrospective study, no significant differences were seen in EVP treatment outcomes based on HER2 IHC status or ERBB2 status. These findings are hypothesis-generating and require validation in larger and prospective cohorts. HER2 0/1+ (n=54)* HER2 2+/3+ (n=58) OR (95%CI, p) HR UVA (95%CI, p) HR MVA (95%CI, p) ORR 49% (23/47) 55% (27/49) 1.3 (0.6-2.9, p=0.5) - - DCR 79% (37/47) 88% (43/49) 1.9 (0.7-6.2, p=0.2) - - mDOR 11.7 mos 10.4 mos - 1.3 (0.7-2.4, p=0.4) 1.2 (0.4-3.3, p=0.8) mPFS 5.9 mos 7.1 mos - 0.8 (0.5-1.4, p=0.5) 1.1 (0.5-2.5, p=0.9) mOS 42.4 mos 18.7 mos - 2.3 (1.1-4.5, p=0.02) 2.0 (0.8-5.4, p=0.2) *HER2 0/1+ used as reference.
Degradable fibrin hydrogels for transplantation of iPSC-derived retinal pigment epithelial cell monolayers
Marmorstein, Alan D. , Knudsen, Travis, Hill, Matthew, Kopp, Francesca N., Trncic, Emma , Korda, David , Atherton, Evan, Berger, Aubrey , Gandhi, Jarel K. , Iezzi, Raymond , Gandhi, Jarel, Marmorstein, Alan D , Scruggs, Brittni A. , Kopp, Francesca, Finnemann, Silvia C.

Mayo Clinic

Frontiers in Cell and Developmental Biology | January 14, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcell.2025.1739620 | PMID 41613944 Get It

Death or dysfunction of retinal pigment epithelium (RPE) cells occurs in age-related macular degeneration (AMD) and certain inherited retinal dystrophies (IRDs). Induced-pluripotent stem cell (iPSC) derived-RPE have been used in early-stage clinical trials to treat AMD and IRDs by injecting them as a cell suspension or monolayers. While RPE transplant shows therapeutic potential, issues ranging from failure to repopulate the entire treatment area, clumping and monolayer folding, and a foreign body response to the support have been reported. We’ve shown that RPE can be grown on high concentration (>30 mg/mL) degradable fibrin hydrogels, and that cell free fibrin hydrogels implanted in the subretinal space degrade without causing inflammation. Here we describe manufacture and surgical implantation of degradable fibrin hydrogels carrying iPSC-RPE into a porcine model of geographic atrophy (GA). Large (15.25 × 58.42 × 0.2 mm) fibrin gel blanks were produced by injection molding, and iPSC-RPE were grown on their surface. Using a mechanical punch, the blank was subdivided into 1.5 × 5.0 × 0.2 mm doses, which fit a custom tool used for storage and surgical placement. Following aseptic packaging, RPE and gels were stable at 37 °C for at least 7 weeks. When transplanted into a pig model of GA, the fibrin scaffold degraded in <1 month and the iPSC-RPE provided partial rescue from GA as assessed by preservation of photoreceptors and blood flow in the choriocapillaris. We conclude that iPSC-RPE delivered on degradable fibrin hydrogels represent a potentially safe and effective approach to RPE transplantation.
Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype
Attipoe, Gilles, Blechner, Michael, Cuker, Adam , Fadeyi, Emmanuel A. , Forbes, Victoria , Francischetti, Ivo M.B. , Gadi, Vijayakrishna K. , Haimed, Abraham , Han, Hyojeong , Haspel, Richard L. , Karafin, Matthew S. , Klein, Kimberly, Kumar, Priyadarshini , Kushnir, Margarita , Lewis, Michael R. , Li, Geling , Brzostek, Sabrina, Rose, Gary S. , Siddon, Alexa J. , Sillings, Christine N., Soni, Amy , Stevens, Don A., Szymanski, James , Takemoto, Clifford M., Warsame, Rahma , Zaghloul, Nibal, Belay, Yadashe, Fink, Aliza K., Frustace, Patricia, Tyson, Jamie, Havre, Nathalie van , Achebe, Maureen , Merz, Lauren E. , Barriteau, Christina M. , Blechner, Michael, Burks, Eric , Calhoun, Cecelia L. , Campbell-Lee, Sally , Chang, Vivian Y. , Chou, Stella T. , Fingrut, Warren , Godby, Richard , Godley, Lucy A. , Ilonze, Chibuzo , Jacquot, Cyril , Ji, Peng Cheng , Juskewitch, Justin E. , Kucine, Nicole , Levitz, David , Lewis, Michael, Mei, Zhen W. , Rose, Gary, Schultz, Corinna L. , Sloan, J. Mark , Story, Charlotte McIlwaine , Thompson, Alexis A. , Weyand, Angela C. , Wilson, Samuel , Belay, Yadashe, Tyson, Jamie

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1074-1074

10.1182/blood-2025-1074 Get It

Abstract Introduction: The Duffy null variant (genotype or phenotype) is associated with lower circulating absolute neutrophil counts (ANC) without increased risk for infection. It is found in ~66% of people identifying as Black or African American vs <1% of people of Asian or European ancestry. Many ANC reference intervals (RI) are not representative of the Duffy null population. There are no adult Duffy null WBC RI and no pediatric Duffy null ANC or WBC RI. Thus, we aimed to assess Duffy null ANC and WBC distributions as well as develop WBC and ANC RI for adults and pediatrics. Methods: Twenty-three sites across the United States collected samples with all sites excluding participants with conditions or medications that could impact ANC or WBC. Only Duffy null participants were included. Sex, race, ethnicity, age, sample collection type, practice setting, Duffy testing method, ANC, and WBC were recorded. The non-parametric method for determining lower limit of normal (LLN), upper limit of normal (ULN), and 90% confidence intervals (CI) around the limits was performed according to the Clinical and Laboratory Standards Institute guidelines. Specific ULN and LLN are not reported as these are preliminary data. The Mann-Whitney U test was used to compare sex and prior data; differences by age groups were assessed with Kruskal-Wallis test. Results: 316 participants 18+ years-old (y/o) were assessed of whom 62.3% (n=197) are female, 97.5% (n=308) identified as Black or African American, and 94.9% (n=300) identified as non-Hispanic. Median age was 47 y/o (IQR: 32-60.5). Median ANC was 2600/uL (IQR: 1860-3530; range: 400-7400); 28.6% (n=90) of participants had ANC <2000/uL, 13.6% (n=43) had ANC <1500/uL, and 2.5% (n=8) had <1000/uL. The 90% CI around the LLN was 810-1070/uL and 5570-7130/uL around the ULN. Consistent with prior data, there was a difference in median ANC by sex (male: 2400/uL; female: 2710/uL; p=0.02). There was no significant difference between this ANC data and previously published Duffy null ANC data (p=0.28). Median WBC was 5.4x109/L (IQR: 4.4-6.5; range: 2.10-11.64) with 4.1% (n=13) of participants with WBC <3.0x109/L. The 90% CI around the LLN is 3.68-4.30x109/L and 11.02-12.97x109/L around the ULN. 515 participants between 0-17 y/o were assessed with 51.8% (n=267) females, 94.8% (n=488) identified as Black or African American, and 94.0% (n=484) identified as non-Hispanic. Among pediatric participants, 56.8% (n=291) had ANC <2000/uL, 38.7% (n=198) had ANC <1500/uL, and 14.4% (n=74) had ANC <1000/uL. For those <1 y/o (n=29), median ANC was 950/uL (IQR: 840-1360; range: 111-3910). There are currently too few samples to predict ULN and LLN. Median WBC was 8.85x109/L (IQR: 7.03-10.16; range: 4.17-13.53). For those 1-5 y/o (n=143), median ANC was 1735/uL (IQR: 1100-2550; range: 207-5810) with a 90% CI around the LLN of 207-820/uL and 4020-5810/uL around the ULN. Median WBC was 6.72x109/L (IQR: 5.64-8.25; range: 3.68-12.97). For those 6-11 y/o (n=128), median ANC was 1590/uL (IQR: 1090-2470; range: 420-5490) with a 90% CI around the LLN of 420-910/uL and 4340-5490/uL around the ULN. Median WBC was 5.42x109/L (IQR: 4.45-6.70; range: 2.80-10.50). For those 12-17 y/o (n=215), median ANC was 2190/uL (IQR: 1460-2930; range: 204-5850) with a 90% CI around the LLN of 540-930/uL and 4350-5510/uL around the ULN. Median WBC was 5.06x109/L (IQR: 4.26-6.20; range of 2.04-9.91). There is a significant difference in ANC by age category (p<0.0001). Conclusion: This is the first report of healthy pediatric Duffy null ANC and WBC data and the first large-scale verification of adult Duffy null ANC and WBC data. Final RI are expected in September 2025. Among adults with the Duffy null phenotype, ANC LLN are likely between 810-1070/uL. Pediatric ANC LLN are likely as low as 207-820/uL (1-5 y/o), 420-910/uL (6-11 y/o), and 540-930/uL (12-17 y/o). These findings redefine “normal” as a significant proportion of healthy participants have ANC or WBC below current RI or below thresholds typically defined as disease. Limitations include heterogeneous sample populations and collection methods. Future analyses will assess differences between collection sites or methods. Ultimately, this work lays the foundation for a more scientifically sound and equitable approach to medical care by ensuring that RI accurately reflects health for the entire community. Healthcare systems are strongly encouraged to adopt Duffy null-specific ANC and WBC RI.
TMIC-78. Aquaporin-4 loss in astrocytes drives glioblastoma-associated cerebral edema and alters the tumor immune microenvironment
Flick, Matthew J. , Garvin, Kaisha, Vallcorba, Montserrat Puigdelloses, Ramos, Susana Isabel , Tsankova, Nadejda M. , Tran, Nhan L. , Hu, Leland , Heiland, Dieter Henrik , Tran, Nhan L , Joshi, Tanvi , Flick, Matthew J, Garvin, Kaisha, Dedhia, Mehek , Chen, Zhihong , Peters, Katherine B. , Smith, Alexander J. , Hambardzumyan, Dolores

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v462-v463

10.1093/neuonc/noaf201.1833 Get It

Abstract Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a dismal 5-year survival rate of ~6.5%. Vasogenic cerebral edema is a severe complication that occurs in the majority of GBM patients, leading to a significant increase in intracranial pressure, neurological deficits, and increased mortality rates. GBM-associated edema is almost exclusively managed by the corticosteroid dexamethasone, the use of which is associated with immunosuppression and interference with radiation therapy. While there is considerable research on edema formation, little is known about how edema resolution occurs in GBM, particularly in response to dexamethasone or other anti-edema therapies. This gap in understanding highlights the need for new approaches to treat edema effectively. The water channel aquaporin-4 (AQP4), a key player in the brain’s water homeostasis, is upregulated in GBM compared to the normal brain. To investigate the role of AQP4 in GBM-associated edema, we used the RCAS/tv-a system to generate de novo GBM with different driver mutations in Aqp4 knockout (KO) and wild-type (WT) mice. Our results indicated that Aqp4 KO tumor-bearing mice had shortened survival and increased edema content. Additionally, Aqp4 loss decreased astrocyte coverage specifically in the tumor core but not the tumor periphery. Our single cell RNA-seq data suggested that Aqp4 loss led to an astrocytic shift towards a less reactive, progenitor-like state, while also decreasing the myeloid and CD8+ T cell population in the tumor microenvironment. Interestingly, tumor-bearing mice treated with anti-VEGFA antibody, which has anti-edema properties, showed increased expression of Aqp4 and reduced vessel leakage. This suggests that AQP4 plays a critical role in mediating the effects of anti-VEGFA therapy. Overall, this study highlights the important role of AQP4 in the resolution of edema, while also revealing its additional effects on astrocyte activation and the immune microenvironment in GBM.
IMG-140. A network-based approach links novel patterns of multiparametric MRI to clinically relevant molecular signatures in high-grade glioma
Kenaston, Matthew W. , Flick, Matthew J. , Sereduk, Christopher, LaFond, Gabe, Langworthy, Jazlynn , Spahiu, Albana, Turkmani, Ali , Krishna, Chandan , Patra, Devi P. , Zimmerman, Richard S. , Swanson, Kristin R. , Tran, Nhan L. , Hu, Leland , Swanson, Kristin R , Tran, Nhan L , Flick, Matthew, Sereduk, Chris , Curtin, Lee , Baxter, Leslie C. , Bendok, Bernard R. , Kannan, Kasthuri S. , Ceccarelli, Michele

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v308-v308

10.1093/neuonc/noaf201.1218 Get It

Abstract High-grade gliomas (HGG) have significant spatial heterogeneity, complicating therapeutic approaches. While multiparametric MRI (mpMRI) enables noninvasive assessment of this heterogeneity, most predictive models lack biological interpretability when used to classify or predict outcomes. Here, we developed an unsupervised framework that identifies novel mpMRI feature patterns through dimensional reduction, linking them to clinically relevant molecular signatures. We analyzed 18 advanced mpMRI features from 73 stereotactic biopsies across 20 HGG patients. Imaging data were normalized, followed by dimensional reduction using an iterative UMAP across varying parameters. Density-based clustering was used to generate stable image-derived clusters through consensus co-clustering. RNA-seq data from matched biopsies were analyzed using DESeq2 and GSEA to identify differentially expressed genes and enriched pathways. We then constructed a network linking specific imaging features to these transcriptional signatures. Validation was performed in an independent cohort, allowing us to extend clusters across full brain mpMRI. Unsupervised clustering of mpMRI features produced nine stable image-based clusters. These clusters were not fully explained by contrast enhancement, metabolic class, or tumor purity, shown by intraclass correlation (ICC) analyses, suggesting they capture novel biological variation. Transcriptomic analysis showed each cluster was associated with distinct gene expression patterns and enriched biological pathways, including neuronal differentiation, immune chemotaxis, and chromatin remodeling. Key imaging features (sRCBV, MTT, K2)—combined in cluster-specific patterns—enabled construction of an interpretable imaging–transcriptomic network. This was validated in an independent cohort. We then applied to full brain mpMRI, mapping spatially distinct regions to biological trends and patient outcomes. Addressing a research gap in imaging HGG, we present an interpretable network that connects specific patterns of mpMRI to clinically meaningful molecular signatures. This approach advances our understanding of tumor heterogeneity and supports future translational work in precision patient care.
STEM-19. OLIG2 AND STAT5 TRANSCRIPTIONAL AXIS DRIVES GLIOMA STEM CELL PROLIFERATION AND INVASION
McNamara, James, Miller, Aunay , Orndorff, Keely, Nascari, David , Blomquist, Mylan, Flick, Matthew J. , Sereduk, Christopher, Loftus, Joseph C. , Hu, Leland , Tran, Nhan L. , Mehta, Shwetal , Tran, Nhan L , Orndorff, Keely, Flick, Matthew, Sereduk, Chris

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v81-v82

10.1093/neuonc/noaf201.0327 Get It

Abstract Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) progression, therapy resistance, and recurrence, making them critical therapeutic targets. While the lineage-defining transcription factor OLIG2 is critical for GSC maintenance, the molecular co-regulators and downstream pathways it engages remain poorly defined. Here, we identify a previously unrecognized, functionally significant interaction between OLIG2 and STAT5B, uncovering a novel regulatory axis in GSCs. Using proximity ligation assay (PLA), we demonstrate that OLIG2 interacts with STAT5 in human and mouse GSC models, particularly in EGFRvIII-mutant cells. We find that OLIG2 preferentially partners with STAT5B and not STAT5A. Knockdown studies in GSCs reveal that OLIG2 and STAT5B co-regulate critical oncogenes BIRC5 and NUSAP1, both of which are required for sphere formation and migration capacity of EGFRvIII positive GSCs. In orthotopic xenograft models, knockdown of either STAT5B or OLIG2 significantly prolongs survival reduces expression of stemness and invasion markers, SOX2, VIMENTIN, and NUSAP1. In contrast, STAT5A knockdown fails to recapitulate these phenotypes, underscoring the role of OLIG2-STAT5B signaling in GSCs. These findings reveal a novel OLIG2-STAT5B transcriptional circuit that plays a role in GSC stemness maintenance, invasion, and tumor growth, particularly in EGFRvIII-driven gliomas. Targeting this axis may offer a new avenue for GBM treatment.